A hybrid discrete-continuum modelling approach for the interactions of the immune system with oncolytic viral infections

David Morselli,Marcello E. Delitala,Adrianne L. Jenner,Federico Frascoli

2024-04-10

Abstract:Oncolytic virotherapy, utilizing genetically modified viruses to combat cancer and trigger anti-cancer immune responses, has garnered significant attention in recent years. In our previous work

Populations and Evolution

What problem does this paper attempt to address?

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

Leticia R Paiva,Hallan S Silva,Silvio C Ferreira,Marcelo L Martins

DOI: https://doi.org/10.1088/1478-3975/10/2/025005

2013-03-15

Physical Biology

Abstract:Oncolytic virotherapy-the use of viruses that specifically kill tumor cells-is an innovative and highly promising route for treating cancer. However, its therapeutic outcomes are mainly impaired by the host immune response to the viral infection. In this paper, we propose a multiscale mathematical model to study how the immune response interferes with the viral oncolytic activity. The model assumes that cytotoxic T cells can induce apoptosis in infected cancer cells and that free viruses can be inactivated by neutralizing antibodies or cleared at a constant rate by the innate immune response. Our simulations suggest that reprogramming the immune microenvironment in tumors could substantially enhance the oncolytic virotherapy in immune-competent hosts. Viable routes to such reprogramming are either in situ virus-mediated impairing of CD8(+) T cells motility or blockade of B and T lymphocytes recruitment. Our theoretical results can shed light on the design of viral vectors or new protocols with neat potential impacts on the clinical practice.

biochemistry & molecular biology,biophysics
Agent-based and continuum models for spatial dynamics of infection by oncolytic viruses

David Morselli,Marcello Edoardo Delitala,Federico Frascoli

DOI: https://doi.org/10.1007/s11538-023-01192-x

2023-09-05

Abstract:The use of oncolytic viruses as cancer treatment has received considerable attention in recent years, however the spatial dynamics of this viral infection is still poorly understood. We present here a stochastic agent-based model describing infected and uninfected cells for solid tumours, which interact with viruses in the absence of an immune response. Two kinds of movement, namely undirected random and pressure-driven movements, are considered: the continuum limit of the models is derived and a systematic comparison between the systems of partial differential equations and the individual-based model, in one and two dimensions, is carried out. In the case of undirected movement, a good agreement between agent-based simulations and the numerical and well-known analytical results for the continuum model is possible. For pressure-driven motion, instead, we observe a wide parameter range in which the infection of the agents remains confined to the center of the tumour, even though the continuum model shows traveling waves of infection; outcomes appear to be more sensitive to stochasticity and uninfected regions appear harder to invade, giving rise to irregular, unpredictable growth patterns. Our results show that the presence of spatial constraints in tumours' microenvironments limiting free expansion has a very significant impact on virotherapy. Outcomes for these tumours suggest a notable increase in variability. All these aspects can have important effects when designing individually tailored therapies where virotherapy is included.

Populations and Evolution,Cell Behavior
Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression

Adrianne L. Jenner,Chae-Ok Yun,Arum Yoon,Adelle C. F. Coster,Peter S. Kim

DOI: https://doi.org/10.1080/23737867.2018.1438216

2018-03-12

Letters in Biomathematics

Abstract:Combined virotherapy and immunotherapy has been emerging as a promising and effective cancer treatment for some time. Intratumoural injections of an oncolytic virus instigate an immune reaction in the host, resulting in an influx of immune cells to the tumour site. Through combining an oncolytic viral vector with immunostimulatory cytokines an additional antitumour immune response can be initiated, whereby immune cells induce apoptosis in both uninfected and virus infected tumour cells. We develop a mathematical model to reproduce the experimental results for tumour growth under treatment with an oncolytic adenovirus co-expressing the immunostimulatory cytokines interleukin 12 (IL-12) and granulocyte-monocyte colony stimulating factor (GM-CSF). By exploring heterogeneity in the immune cell stimulation by the treatment, we find a subset of the parameter space for the immune cell induced apoptosis rate, in which the treatment will be less effective in a short time period. Therefore, we believe the bivariate nature of treatment outcome, whereby tumours are either completely eradicated or grow unbounded, can be explained by heterogeneity in this immune characteristic. Furthermore, the model highlights the apparent presence of negative feedback in the helper T cell and APC stimulation dynamics, when IL-12 and GM-CSF are co-expressed as opposed to individually expressed by the viral vector.
Mathematical modelling of the interaction between cancer cells and an oncolytic virus: insights into the effects of treatment protocols

Adrianne L. Jenner,Chae-Ok Yun,Peter S. Kim,Adelle C. F. Coster,Adelle C.F. Coster

DOI: https://doi.org/10.48550/arXiv.1911.12876

2019-11-28

Cell Behavior

Abstract:Oncolytic virotherapy is an experimental cancer treatment that uses genetically engineered viruses to target and kill cancer cells. One major limitation of this treatment is that virus particles are rapidly cleared by the immune system, preventing them from arriving at the tumour site. To improve virus survival and infectivity modified virus particles with the polymer polyethylene glycol (PEG) and the monoclonal antibody herceptin. While PEG modification appeared to improve plasma retention and initial infectivity it also increased the virus particle arrival time. We derive a mathematical model that describes the interaction between tumour cells and an oncolytic virus. We tune our model to represent the experimental data by Kim et al. (2011) and obtain optimised parameters. Our model provides a platform from which predictions may be made about the response of cancer growth to other treatment protocols beyond those in the experiments. Through model simulations we find that the treatment protocol affects the outcome dramatically. We quantify the effects of dosage strategy as a function of tumour cell replication and tumour carrying capacity on the outcome of oncolytic virotherapy as a treatment. The relative significance of the modification of the virus and the crucial role it plays in optimising treatment efficacy is explored.
Virus-Based Immuno-Oncology Models

Juliana Sitta,Pier Paolo Claudio,Candace M Howard

DOI: https://doi.org/10.3390/biomedicines10061441

IF: 4.757

2022-06-18

Biomedicines

Abstract:Immunotherapy has been extensively explored in recent years with encouraging results in selected types of cancer. Such success aroused interest in the expansion of such indications, requiring a deep understanding of the complex role of the immune system in carcinogenesis. The definition of hot vs. cold tumors and the role of the tumor microenvironment enlightened the once obscure understanding of low response rates of solid tumors to immune check point inhibitors. Although the major scope found in the literature focuses on the T cell modulation, the innate immune system is also a promising oncolytic tool. The unveiling of the tumor immunosuppressive pathways, lead to the development of combined targeted therapies in an attempt to increase immune infiltration capability. Oncolytic viruses have been explored in different scenarios, in combination with various chemotherapeutic drugs and, more recently, with immune check point inhibitors. Moreover, oncolytic viruses may be engineered to express tumor specific pro-inflammatory cytokines, antibodies, and antigens to enhance immunologic response or block immunosuppressive mechanisms. Development of preclinical models capable to replicate the human immunologic response is one of the major challenges faced by these studies. A thorough understanding of immunotherapy and oncolytic viruses' mechanics is paramount to develop reliable preclinical models with higher chances of successful clinical therapy application. Thus, in this article, we review current concepts in cancer immunotherapy including the inherent and synthetic mechanisms of immunologic enhancement utilizing oncolytic viruses, immune targeting, and available preclinical animal models, their advantages, and limitations.
Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy

Darshak K. Bhatt,Toos Daemen

DOI: https://doi.org/10.3390/ijms25094691

IF: 5.6

2024-04-26

International Journal of Molecular Sciences

Abstract:Oncolytic virotherapy is a promising immunotherapy approach for cancer treatment that utilizes viruses to preferentially infect and eliminate cancer cells while stimulating the immune response. In this review, we synthesize the current literature on the molecular circuits of immune sensing and response to oncolytic virotherapy, focusing on viral DNA or RNA sensing by infected cells, cytokine and danger-associated-signal sensing by neighboring cells, and the subsequent downstream activation of immune pathways. These sequential sense-and-response mechanisms involve the triggering of molecular sensors by viruses or infected cells to activate transcription factors and related genes for a breadth of immune responses. We describe how the molecular signals induced in the tumor upon virotherapy can trigger diverse immune signaling pathways, activating both antigen-presenting-cell-based innate and T cell-based adaptive immune responses. Insights into these complex mechanisms provide valuable knowledge for enhancing oncolytic virotherapy strategies.

biochemistry & molecular biology,chemistry, multidisciplinary
Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus

A. Finizio,P. Pagano,A. Napolano,G. Froechlich,L. Infante,A. De Chiara,S. Amiranda,E. Vitiello,S. Totaro,C. Capasso,M. Raia,A. M. D'Alise,P. de Candia,N. Zambrano,E. Sasso

DOI: https://doi.org/10.1038/s41417-024-00790-8

IF: 5.854

2024-06-05

Cancer Gene Therapy

Abstract:Systems biology has been applied at the multi-scale level within the cancer field, improving cancer prevention, diagnosis and enabling precision medicine approaches. While systems biology can expand the knowledge and skills for oncological treatment, it also represents a challenging expedition due to cancer complexity, heterogeneity and diversity not only between different cancer indications, but also in its evolution process through space and time. Here, by characterizing the transcriptional perturbations of the tumor microenvironment induced by oncolytic, we aimed to rationally design a novel armed oncolytic herpes virus. We found that intratumor oncovirotherapy with HSV-1 induces T-cell activation signatures and transcriptionally activates several costimulatory molecules. We identified differentially expressed costimulatory receptors and binding partners, where inducible co-stimulators (ICOS) resulted in the potentially most beneficial targeted therapy. Through an ex-vivo transcriptomic analysis, we explored the potential of arming an oncolytic virus as a combination therapy strategy; in particular, we engineered a targeted herpes virus encoding ICOSL (THV_ICOSL), which resulted in a significant improvement in tumor size control compared to unarmed parental virus. Also, combination with a PD-1 inhibitor enhanced antitumor efficacy as predictable by upregulation of PD-1 and ligands pair (PD-L1/PD-L2) upon oncolytic virus injection. Generation of the human version of this virus encoding hICOSL orthologue effectively and specifically activated human T cells by triggering the ICOS pathway. Our data support the data-driven generation of armed oncolytic viruses as combination immunotherapeutic with checkpoint inhibitors.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Integrating oncolytic viruses in combination cancer immunotherapy

Praveen K. Bommareddy,Megha Shettigar,Howard L. Kaufman

DOI: https://doi.org/10.1038/s41577-018-0014-6

IF: 108.555

2018-05-09

Nature Reviews Immunology

Abstract:Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells, leading to the release of soluble antigens, danger signals and type I interferons, which drive antitumour immunity. In addition, some oncolytic viruses can be engineered to express therapeutic genes or can functionally alter tumour-associated endothelial cells, further enhancing T cell recruitment into immune-excluded or immune-deserted tumour microenvironments. Oncolytic viruses can also utilize established tumours as an in situ source of neoantigen vaccination through cross-presentation, resulting in regression of distant, uninfected tumours. These features make oncolytic viruses attractive agents for combination strategies to optimize cancer immunotherapy.

immunology
Cutting both ways: the innate immune response to oncolytic virotherapy

David Mealiea,J. Andrea McCart

DOI: https://doi.org/10.1038/s41417-021-00351-3

IF: 5.854

2021-08-27

Cancer Gene Therapy

Abstract:Oncolytic viruses (OVs), above and beyond infecting and lysing malignant cells, interact with the immune system in complex ways that have important therapeutic significance. While investigation into these interactions is still in its early stages, important insights have been made over the past two decades that will help improve the clinical efficacy of OV-based management strategies in cancer care moving forward. The inherent immunosuppression that defines the tumor microenvironment can be modified by OV infection, and the subsequent recruitment and activation of innate immune cells, in particular, is central to this. Indeed, neutrophils, macrophages, natural killer cells, and dendritic cells, as well as other populations such as myeloid-derived suppressor cells, are key to the immune escape that allows tumors to survive, but their natural response to infection can be exploited by virotherapy. While stimulation of innate immune cells by OVs can initiate antitumor responses, related antiviral activity can limit virus spread and direct cytopathogenic effects. In this review, we highlight how each innate immune cell population influences this balance of antitumor and antiviral forces during virotherapy, some of the important molecular pathways that have been identified, and specific therapeutic targets that have emerged through this work. We discuss the importance of OV-based combination therapies in optimizing antiviral and antitumor innate immune responses stimulated by virotherapy toward tumor eradication, and how these processes vary depending on the tumor and OV in question. Rather than concentrating on a particular OV species in the review, we present the range of effects that have been documented across OV types to emphasize the context-specific nature of these interactions and how this is important in the design of future OV-based treatment approaches.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Oncolytic Viruses in Cancer Immunotherapy

Xiao Li,Zhongping Cheng

DOI: https://doi.org/10.1002/adtp.202300445

IF: 5.003

2024-03-11

Advanced Therapeutics

Abstract:Abstract Oncolytic viruses are novel and promising therapeutic regimens that promote antitumor efficacy through multimode mechanisms, including direct lysis of tumor cells, release of the tumor antigens and danger signals, induction of immunological cell death, activation of innate and adaptive immune response. In addition, oncolytic viruses can be engineered to express virus‐centered and immune‐centered therapeutic transgenes, further transforming the “cold” tumor into “hot” and enhancing the oncolytic efficacy. Several oncolytic viruses have been engineered and widely used as potential therapeutic agents for many cancers and the therapeutic strategies and effectiveness vary among different types of oncolytic viruses. Finally, oncolytic viruses‐based combination immunotherapy has been practiced in preclinical and clinical studies, and indicated that combination oncolytic viruses with conventional therapy or immunomodulatory agents exerted favorable antitumor efficacy. This article is protected by copyright. All rights reserved

English Else
A hybrid discrete-continuum modelling approach to explore the impact of T-cell infiltration on anti-tumour immune response

Luis Almeida,Chloe Audebert,Emma Leschiera,Tommaso Lorenzi

DOI: https://doi.org/10.48550/arXiv.2207.09110

2022-10-07

Abstract:We present a spatial hybrid discrete-continuum modelling framework for the interaction dynamics between tumour cells and cytotoxic T cells, which play a pivotal role in the immune response against tumours. In this framework, tumour cells and T cells are modelled as individual agents while chemokines that drive the chemotactic movement of T cells towards the tumour are modelled as a continuum. We formally derive the continuum counterpart of this model, which is given by a coupled system that comprises an integro-differential equation for the density of tumour cells, a partial differential equation for the density of T cells, and a partial differential equation for the concentration of chemokines. We report on computational results of the hybrid model and show that there is an excellent quantitative agreement between them and numerical solutions of the corresponding continuum model. These results shed light on the mechanisms that underlie the emergence of different levels of infiltration of T cells into the tumour and elucidate how T-cell infiltration shapes anti-tumour immune response. Moreover, to present a proof of concept for the idea that, exploiting the computational efficiency of the continuum model, extensive numerical simulations could be carried out, we investigate the impact of T-cell infiltration on the response of tumour cells to different types of anti-cancer immunotherapy.

Analysis of PDEs
Treating cancerous cells with a continuous release of virus particles

Ahmed Msmali,Mark Nelson,Fahad Al Saadi

DOI: https://doi.org/10.21914/anziamj.v63.17108

2022-12-07

Abstract:We investigate a model for the treatment of a tumour through the application of a virus. In the original model it was assumed that the virus particles are released only at one time. Such a treatment strategy cannot eliminate a tumour, as the tumour-free steady-state solution is unstable except for pathological circumstances in which the tumour does not grow and/or the virus does not die. We extend the model by allowing the tumour to be treated by a continuous release of virus particles. We show that the scaled delivery rate has two threshold values: below the lower threshold the system evolves to a stable periodic solution; above the higher threshold the tumour is eradicated. References C. E. Engeland, J. P. W. Heidbuechel, R. P. Araujo, and A. L. Jenner. Improving immunovirotherapies: The intersection of mathematical modelling and experiments. ImmunoInformatics 6 (2022), p. 100011. doi: 10.1016/j.immuno.2022.100011 A. L. Jenner, A. C. F. Coster, P. S. Kim, and F. Frascoli. Treating cancerous cells with viruses. Lett. Biomath. 5.2 (2018), S117–S136. doi: 10.1080/23737867.2018.1440977 A. L. Jenner, F. Frascoli, C.-O. Yun, and P. S. Kim. Optimising hydrogel release profiles for viro-immunotherapy using oncolytic adenovirus expressing IL-12 and GM-CSF with immature dendritic cells. Appl. Sci. 10.8 (2020). doi: 10.3390/app10082872 J. P. Tian. The replicability of oncolytic virus: Defining conditions in tumor virotherapy. Math. Bio. Eng. 8.3 (2011), pp. 841–860. doi: 10.3934/mbe.2011.8.841

mathematics, applied
A phenotype-structured mathematical model for the influence of hypoxia on oncolytic virotherapy

David Morselli,Giulia Chiari,Federico Frascoli,Marcello E. Delitala

2024-10-21

Abstract:The effectiveness of oncolytic virotherapy is significantly affected by several elements of the tumour microenvironment, which reduce the ability of the virus to infect cancer cells. In this work, we focus on the influence of hypoxia on this therapy and develop a novel continuous mathematical model that considers both the spatial and epigenetic heterogeneity of the tumour. We investigate how oxygen gradients within tumours affect the spatial distribution and replication of both the tumour and oncolytic viruses, focusing on regions of severe hypoxia versus normoxic areas. Additionally, we analyse the evolutionary dynamics of tumour cells under hypoxic conditions and their influence on susceptibility to viral infection. Our findings show that the reduced metabolic activity of hypoxic cells may significantly impact the virotherapy effectiveness; the knowledge of the tumour's oxygenation could, therefore, suggest the most suitable type of virus to optimise the outcome. The combination of numerical simulations and theoretical results for the model equilibrium values allows us to elucidate the complex interplay between viruses, tumour evolution and oxygen dynamics, ultimately contributing to developing more effective and personalised cancer treatments.

Tissues and Organs,Populations and Evolution
The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study

Pantea Pooladvand,Chae-Ok Yun,A-Rum Yoon,Peter S. Kim,Federico Frascoli

DOI: https://doi.org/10.48550/arXiv.2110.03357

2021-10-07

Dynamical Systems

Abstract:A model capturing the dynamics between virus and tumour cells in the context of oncolytic virotherapy is presented and analysed. The ability of the virus to be internalised by uninfected cells is described by an infectivity parameter, which is inferred from available experimental data. The parameter is also able to describe the effects of changes in the tumour environment that affect viral uptake from tumour cells. Results show that when a virus is inoculated inside a growing tumour, strategies for enhancing infectivity do not lead to a complete eradication of the tumour. Within typical times of experiments and treatments, we observe the onset of oscillations, which always prevent a full destruction of the tumour mass. These findings are in good agreement with available laboratory results. Further analysis shows why a fully successful therapy cannot exist for the proposed model and that care must be taken when designing and engineering viral vectors with enhanced features. In particular, bifurcation analysis reveals that creating longer lasting virus particles or using strategies for reducing infected cell lifespan can cause unexpected and unwanted surges in the overall tumour load over time. Our findings suggest that virotherapy alone seems unlikely to be effective in clinical settings unless adjuvant strategies are included.
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer

Salaheldin Omer,Hermane Mambili-Mamboundou

DOI: https://doi.org/10.1007/s12190-024-02139-8

2024-06-20

Journal of Applied Mathematics and Computing

Abstract:Combined oncolytic virotherapy and immunotherapy are novel treatment protocols that represent a promising and advantageous strategy for various cancers, surpassing conventional anti-cancer treatments. This is due to the reduced toxicity associated with traditional cancer therapies. We present a mathematical model that describes the interactions between tumor cells, the immune response, and the combined application of virotherapy and interleukin-2 (IL-2). A stability analysis of the model for both the tumor and tumor-free states is discussed. To gain insight into the impact of model parameters on tumor cell growth and inhibition, we perform a sensitivity analysis using Latin hypercube sampling to compute partial rank correlation coefficient values and their associated p -values. Furthermore, we perform optimal control techniques using the Pontryagin maximum principle to minimize tumor burden and determine the most effective protocol for the administered treatment. We numerically demonstrate the ability of combined virotherapy and IL-2 to eliminate tumors.

mathematics, applied
Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Hai Zou,Xiao-Zhou Mou,Biao Zhu

DOI: https://doi.org/10.1002/gch2.202200094

2022-10-20

Abstract:Oncolytic viruses have found a good place in the treatment of cancer. Administering oncolytic viruses directly or by applying genetic changes can be effective in cancer treatment through the lysis of tumor cells and, in some cases, by inducing immune system responses. Moreover, oncolytic viruses induce antitumor immune responses via releasing tumor antigens in the tumor microenvironment (TME) and affect tumor cell growth and metabolism. Despite the success of virotherapy in cancer therapies, there are several challenges and limitations, such as immunosuppressive TME, lack of effective penetration into tumor tissue, low efficiency in hypoxia, antiviral immune responses, and off-targeting. Evidence suggests that oncolytic viruses combined with cancer immunotherapy-based methods such as immune checkpoint inhibitors and adoptive cell therapies can effectively overcome these challenges. This review summarizes the latest data on the use of oncolytic viruses for the treatment of cancer and the challenges of this method. Additionally, the effectiveness of mono, dual, and triple therapies using oncolytic viruses and other anticancer agents has been discussed based on the latest findings.
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Marc Lecoultre,Paul R. Walker,Aya El Helali

DOI: https://doi.org/10.1007/s10238-024-01443-8

IF: 4.6

2024-08-31

Clinical and Experimental Medicine

Abstract:Oncolytic viruses (OV) are a promising strategy in cancer immunotherapy. Their capacity to promote anti-tumoral immunity locally raises hope that cancers unresponsive to current immunotherapy approaches could be tackled more efficiently. In this context, tumor-associated macrophages (TAM) must be considered because of their pivotal role in cancer immunity. Even though TAM tend to inhibit anti-tumoral responses, their ability to secrete pro-inflammatory cytokines and phagocytose cancer cells can be harnessed to promote therapeutic cancer immunity. OVs have the potential to promote TAM pro-inflammatory functions that favor anti-tumoral immunity. But in parallel, TAM pro-inflammatory functions induce OV clearance in the tumor, thereby limiting OV efficacy and highlighting that the interaction between OV and TAM is a double edge sword. Moreover, engineered OVs were recently developed to modulate specific TAM functions such as phagocytic activity. The potential of circulating monocytes to deliver OV into the tumor after intravenous administration is also emerging. In this review, we will present the interaction between OV and TAM, the potential of engineered OV to modulate specific TAM functions, and the promising role of circulating monocytes in OV delivery to the tumor.

medicine, research & experimental
Questing for an optimal, universal viral agent for oncolytic virotherapy

L. R. Paiva,M. L. Martins,S. C. Ferreira

DOI: https://doi.org/10.1103/physreve.84.041918

IF: 2.707

2011-10-17

Physical Review E

Abstract:One of the most promising strategies to treat cancer is attacking it with viruses designed to exploit specific altered pathways. Here, the effects of oncolytic virotherapy on tumors having compact, papillary, and disconnected morphologies are investigated through computer simulations of a multiscale model coupling macroscopic reaction-diffusion equations for the nutrients with microscopic stochastic rules for the actions of individual cells and viruses. The interaction among viruses and tumor cells involves cell infection, intracellular virus replication, and the release of new viruses in the tissue after cell lysis. The evolution over time of both the viral load and cancer cell population, as well as the probabilities for tumor eradication, were evaluated for a range of multiplicities of infection, viral entries, and burst sizes. It was found that in immunosuppressed hosts, the antitumor efficacy of a virus is primarily determined by its entry efficiency, its replicative capacity within the tumor, and its ability to spread over the tissue. However, the optimal traits for oncolytic viruses depend critically on the tumor growth dynamics and do not necessarily include rapid replication, cytolysis, or spreading, currently assumed as necessary conditions for a successful therapeutic outcome. Our findings have potential implications on the design of new vectors for the viral therapy of cancer.

physics, fluids & plasmas, mathematical
Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

Teresa T Nguyen,Dong Ho Shin,Sagar Sohoni,Sanjay K Singh,Yisel Rivera-Molina,Hong Jiang,Xuejun Fan,Joy Gumin,Frederick F Lang,Christopher Alvarez-Breckenridge,Filipa Godoy-Vitorino,Lisha Zhu,W Jim Zheng,Lijie Zhai,Erik Ladomersky,Kristen L Lauing,Marta M Alonso,Derek A Wainwright,Candelaria Gomez-Manzano,Juan Fueyo

DOI: https://doi.org/10.1136/jitc-2022-004935

IF: 12.469

2022-07-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Oncolytic viruses are considered part of immunotherapy and have shown promise in preclinical experiments and clinical trials. Results from these studies have suggested that tumor microenvironment remodeling is required to achieve an effective response in solid tumors. Here, we assess the extent to which targeting specific mechanisms underlying the immunosuppressive tumor microenvironment optimizes viroimmunotherapy. Methods We used RNA-seq analyses to analyze the transcriptome, and validated the results using Q-PCR, flow cytometry, and immunofluorescence. Viral activity was analyzed by replication assays and viral titration. Kyn and Trp metabolite levels were quantified using liquid chromatography–mass spectrometry. Aryl hydrocarbon receptor (AhR) activation was analyzed by examination of promoter activity. Therapeutic efficacy was assessed by tumor histopathology and survival in syngeneic murine models of gliomas, including Indoleamine 2,3-dioxygenase (IDO)-/- mice. Flow cytometry was used for immunophenotyping and quantification of cell populations. Immune activation was examined in co-cultures of immune and cancer cells. T-cell depletion was used to identify the role played by specific cell populations. Rechallenge experiments were performed to identify the development of anti-tumor memory. Results Bulk RNA-seq analyses showed the activation of the immunosuppressive IDO-kynurenine-AhR circuitry in response to Delta-24-RGDOX infection of tumors. To overcome the effect of this pivotal pathway, we combined Delta-24-RGDOX with clinically relevant IDO inhibitors. The combination therapy increased the frequency of CD8 + T cells and decreased the rate of myeloid-derived suppressor cell and immunosupressive Treg tumor populations in animal models of solid tumors. Functional studies demonstrated that IDO-blockade-dependent activation of immune cells against tumor antigens could be reversed by the oncometabolite kynurenine. The concurrent targeting of the effectors and suppressors of the tumor immune landscape significantly prolonged the survival in animal models of orthotopic gliomas. Conclusions Our data identified for the first time the in vivo role of IDO-dependent immunosuppressive pathways in the resistance of solid tumors to oncolytic adenoviruses. Specifically, the IDO-Kyn-AhR activity was responsible for the resurface of local immunosuppression and resistance to therapy, which was ablated through IDO inhibition. Our data indicate that combined molecular and immune therapy may improve outcomes in human gliomas and other cancers treated with virotherapy.

oncology,immunology
On the Treatment of Melanoma: A Mathematical Model of Oncolytic Virotherapy

Tedi Ramaj,Xingfu Zou

DOI: https://doi.org/10.1016/j.mbs.2023.109073

2023-09-02

Abstract:We develop and analyze a mathematical model of oncolytic virotherapy in the treatment of melanoma. We begin with a special, local case of the model, in which we consider the dynamics of the tumour cells in the presence of an oncolytic virus at the primary tumour site. We then consider the more general regional model, in which we incorporate a linear network of lymph nodes through which the tumour cells and the oncolytic virus may spread. The modelling also considers the impact of hypoxia on the disease dynamics. The modelling takes into account both the effects of hypoxia on tumour growth and spreading, as well as the impact of hypoxia on oncolytic virotherapy as a treatment modality. We find that oxygen-rich environments are favourable for the use of adenoviruses as oncolytic agents, potentially suggesting the use of complementary external oxygenation as a key aspect of treatment. Furthermore, the delicate balance between a virus' infection capabilities and its oncolytic capabilities should be considered when engineering an oncolytic virus. If the virus is too potent at killing tumour cells while not being sufficiently effective at infecting them, the infected tumour cells are destroyed faster than they are able to infect additional tumour cells, leading less favourable clinical results. Numerical simulations are performed in order to support the analytic results and to further investigate the impact of various parameters on the outcomes of treatment. Our modelling provides further evidence indicating the importance of three key factors in treatment outcomes: tumour microenvironment oxygen concentration, viral infection rates, and viral oncolysis rates. The numerical results also provide some estimates on these key model parameters which may be useful in the engineering of oncolytic adenoviruses.

Dynamical Systems,Quantitative Methods,Tissues and Organs

A hybrid discrete-continuum modelling approach for the interactions of the immune system with oncolytic viral infections

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

Agent-based and continuum models for spatial dynamics of infection by oncolytic viruses

Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression

Mathematical modelling of the interaction between cancer cells and an oncolytic virus: insights into the effects of treatment protocols

Virus-Based Immuno-Oncology Models

Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy

Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus

Integrating oncolytic viruses in combination cancer immunotherapy

Cutting both ways: the innate immune response to oncolytic virotherapy

Oncolytic Viruses in Cancer Immunotherapy

A hybrid discrete-continuum modelling approach to explore the impact of T-cell infiltration on anti-tumour immune response

Treating cancerous cells with a continuous release of virus particles

A phenotype-structured mathematical model for the influence of hypoxia on oncolytic virotherapy

The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study

Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Questing for an optimal, universal viral agent for oncolytic virotherapy

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

On the Treatment of Melanoma: A Mathematical Model of Oncolytic Virotherapy